AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

alpha-Norgestrel

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

46 API Suppliers, 28 USDMF, 11 CEP/COS, 4 JDMF, 6 EU WC, 20 NDC API, 15 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

24 Drugs in Development

24 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

289 FDF Dossiers, 136 FDA Orange Book, 80 Europe, 30 Canada, 3 Australia, 21 South Africa, 19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL-28 - 0.03MG;0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A, SYSTEM;INTRAUTERINE - 52MG, TABLET;ORAL - 0.02MG;0.1MG, SYSTEM;INTRAUTERINE - 52MG, FILM, EXTENDED RELEASE;TRANSDERMAL - 0.045MG/24HR;0.015MG/24HR, TABLET;ORAL - 1.5MG

RELATED EXCIPIENT COMPANIES

5 SPI Pharma, 9 DKSH, 5 Faran Shimi Pharmaceutical, 4 Boai NKY Pharmaceuticals Ltd, 4 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 17 BASF, 11 Corel Pharma Chem, 5 DFE Pharma, 1 Doshion Polyscience, 1 Finar, 7 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 3 Ingredion Pharma Solutions, 29 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 11 Microlex e.U, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 17 Roquette, 7 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 11 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

65 Fillers, Diluents & Binders, 44 Coating Systems & Additives, 27 Controlled & Modified Release, 23 Thickeners and Stabilizers, 22 Disintegrants & Superdisintegrants, 22 Direct Compression, 20 Granulation, 13 Solubilizers, 13 Lubricants & Glidants, 11 Co-Processed Excipients, 10 Taste Masking, 9 Empty Capsules, 8 Film Formers & Plasticizers, 7 Topical, 6 Chewable & Orodispersible Aids, 5 API Stability Enhancers, 5 Rheology Modifiers, 4 Vegetarian Capsules, 4 Coloring Agents, 4 Emulsifying Agents, 3 Parenteral

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 79 News #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions, 67 Regulatory FDF Prices, 14 Annual Reports

MARKET PLACE

8 APIs, 5 FDF Dossiers

PATENTS & EXCLUSIVITIES

20 US Patents, 2 US Exclusivities

REF. STANDARDS & IMPURITIES

5 EDQM, 3 USP, 1 JP, 8 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
24/02/2025	Bayer AG	Germany	BAYER AG Leverkusen DE	R1-CEP 2000-101 - Rev 03	Levonorgestrel, Micro 20	2017-03-03	Valid	Chemical		926
24/02/2025	Gedeon Richter	Hungary	GEDEON RICHTER PLC Budapest HU	R1-CEP 1999-141 - Rev 04	Levonorgestrel	2021-12-20	Valid	Chemical		926

Alpha-Norgestrel

alpha-Norgestrel

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

46 API Suppliers

28 USDMF

11 CEP/COS

4 JDMF

6 EU WC

20 NDC API

15 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

24 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

289 FDF Dossiers

136 FDA Orange Book

80 Europe

30 Canada

3 Australia

21 South Africa

19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL-28 - 0.03MG;0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A

SYSTEM;INTRAUTERINE - 52MG

TABLET;ORAL - 0.02MG;0.1MG

SYSTEM;INTRAUTERINE - 52MG

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.045MG/24HR;0.015MG/24HR

TABLET;ORAL - 1.5MG

RELATED EXCIPIENT COMPANIES

5 SPI Pharma

9 DKSH

5 Faran Shimi Pharmaceutical

4 Boai NKY Pharmaceuticals Ltd

4 Gangwal Healthcare

1 Nanjing Well Pharmaceutical

4 ACG Worldwide

3 Actylis

1 Aeon Procare

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

17 BASF

11 Corel Pharma Chem

5 DFE Pharma

1 Doshion Polyscience

1 Finar

7 Gangwal Chemicals

5 Ideal Cures Pvt Ltd

3 Ingredion Pharma Solutions

29 Kerry

3 Kima Chemical

6 Lonza Capsugel

11 Microlex e.U

2 Nomisma Healthcare

2 Novo Excipients

2 Pharmatrans-Sanaq

5 Pluviaendo

3 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

17 Roquette

7 Seppic

7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

11 Sigachi Industries

2 The Dow Chemical Company

1 Ulanqab Kema New Material

1 Valens Pharmachem

3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

65 Fillers, Diluents & Binders

44 Coating Systems & Additives

27 Controlled & Modified Release

23 Thickeners and Stabilizers

22 Disintegrants & Superdisintegrants

TABLET;ORAL-28 - 0.03MG;0.3MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons